ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correction
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamaya, M
Right arrow Articles by Yamara, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamaya, M
Right arrow Articles by Yamara, M
Eur Respir J 1999; 13: 757-760
Copyright © ERS Journals Ltd 1999

Original Articles

Exhaled carbon monoxide levels during treatment of acute asthma

M Yamaya, K Sekizawa, S Ishizuka, M Monma, H Sasaki, and M Yamara

Carbon monoxide is known to be present in measurable quantities in the exhaled air of normal subjects and at higher concentrations in asthmatic patients not treated with glucocorticoids. To examine whether exhaled CO is useful in monitoring asthma control, time course changes in peak expiratory flow rate (PEFR) and exhaled CO concentration before and after treatment of acute asthma exacerbations were measured in 20 asthmatic patients. Exhaled CO was measured in triplicate by a portable CO analyser. Exhaled CO was reproducible at all time points. Asthma exacerbations caused a fall in PEFR and a rise in exhaled CO (towards an average of 3.3 parts per million (ppm)) in all patients, and treatment with oral glucocorticoids reversed these changes in both parameters. An improvement of PEFR was closely associated with a reduction of exhaled CO (to an average of 1.5 ppm) after treatment. The maximal exhaled CO concentration significantly correlated with recovery time of PEFR after treatment with oral glucocorticoids (p<0.01). The present study suggests that exhaled CO may be a useful noninvasive means of monitoring the control of asthma.


This article has been cited by other articles:


Home page
 Am. J. Respir. Cell Mol. Bio.Home page
L. E. Fredenburgh, M. A. Perrella, and S. A. Mitsialis
The Role of Heme Oxygenase-1 in Pulmonary Disease
Am. J. Respir. Cell Mol. Biol., February 1, 2007; 36(2): 158 - 165.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
W. Cao and Y. Duan
Breath Analysis: Potential for Clinical Diagnosis and Exposure Assessment
Clin. Chem., May 1, 2006; 52(5): 800 - 811.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
D. Morse and A. M. K. Choi
Heme Oxygenase-1: From Bench to Bedside
Am. J. Respir. Crit. Care Med., September 15, 2005; 172(6): 660 - 670.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
H. Yasuda, M. Yamaya, K. Nakayama, S. Ebihara, T. Sasaki, S. Okinaga, D. Inoue, M. Asada, M. Nemoto, and H. Sasaki
Increased Arterial Carboxyhemoglobin Concentrations in Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med., June 1, 2005; 171(11): 1246 - 1251.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
H. Yasuda, T. Sasaki, M. Yamaya, S. Ebihara, M. Maruyama, A. Kanda, and H. Sasaki
Increased Arteriovenous Carboxyhemoglobin Differences in Patients With Inflammatory Pulmonary Diseases
Chest, June 1, 2004; 125(6): 2160 - 2168.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
P. Paredi, S.A. Kharitonov, and P.J. Barnes
Exhaled carbon monoxide in lung disease
Eur. Respir. J., January 1, 2003; 21(1): 197 - 197.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
P. Paredi, S. A. Kharitonov, and P. J. Barnes
Analysis of Expired Air for Oxidation Products
Am. J. Respir. Crit. Care Med., December 15, 2002; 166(12): S31 - 37.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
S A Kharitonov, L E Donnelly, P Montuschi, M Corradi, J V Collins, and P J Barnes
Dose-dependent onset and cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in mild asthma
Thorax, October 1, 2002; 57(10): 889 - 896.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
H Yasuda, M Yamaya, M Yanai, T Ohrui, and H Sasaki
Increased blood carboxyhaemoglobin concentrations in inflammatory pulmonary diseases
Thorax, September 1, 2002; 57(9): 779 - 783.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J.O.N. Lundberg, J. Palm, and K. Alving
Nitric oxide but not carbon monoxide is continuously released in the human nasal airways
Eur. Respir. J., July 1, 2002; 20(1): 100 - 103.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
D. Morse and A. M. K. Choi
Heme Oxygenase-1 . The "Emerging Molecule" Has Arrived
Am. J. Respir. Cell Mol. Biol., July 1, 2002; 27(1): 8 - 16.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
I. Horvath, W. MacNee, F.J. Kelly, P.N.R. Dekhuijzen, M. Phillips, G. Doring, A.M.K. Choi, M. Yamaya, F.H. Bach, D. Willis, et al.
"Haemoxygenase-1 induction and exhaled markers of oxidative stress in lung diseases", summary of the ERS Research Seminar in Budapest, Hungary, September, 1999
Eur. Respir. J., August 1, 2001; 18(2): 420 - 430.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. A. KHARITONOV and P. J. BARNES
Exhaled Markers of Pulmonary Disease
Am. J. Respir. Crit. Care Med., June 1, 2001; 163(7): 1693 - 1722.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the European Respiratory Society.